Table Head

Value

base-case

sensitivity analysis

Cost for CTZ group, including neoadjuvant chemotherapy and surgery (USD)

8153.7

+25%

10,192.1

8122.1

−25%

6115.3

4215.8

Utility value of stable state

0.89

+11%

1

4710.2

−20%

0.7

13265.1

Duration of progression and hormonal chemotherapy state (months)

18

+6

24

6049.7

−6

12

6265.5

Cost of progression and chemotherapy state (USD)

+25%

1841.3

5856.2

−25%

1104.8

6481.8